Neurotransmitter-mediated action of an antagonist of growth hormone-releasing hormone on anxiolysis in mice

Behavioural Brain Research

Volumn 233, Issue 1, 2012, Pages 232-236

  Telegdy, Gyula ^a   Schally, Andrew V ^b  

^a UNIVERSITY OF SZEGED   (Hungary)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Anxiety; GH RH antagonist; MZ 4 71; Transmitter interactions

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR; ALPHA 1 ADRENERGIC RECEPTOR; ALPHA 2 ADRENERGIC RECEPTOR; ANXIOLYTIC AGENT; BICUCULLINE; CYPROHEPTADINE; GROWTH HORMONE RELEASING FACTOR; METHYSERGIDE; MZ 4 71; NEUROTRANSMITTER; PHENOXYBENZAMINE; PRAZOSIN; SEROTONIN 1 RECEPTOR; SEROTONIN 2 RECEPTOR; UNCLASSIFIED DRUG; YOHIMBINE;

ADRENERGIC SYSTEM; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; GABAERGIC SYSTEM; MALE; MAZE TEST; MENTAL TEST; MOUSE; NONHUMAN; PRIORITY JOURNAL; SEROTONINERGIC SYSTEM; TRANQUILIZING ACTIVITY;

ANALYSIS OF VARIANCE; ANIMALS; ANTI-ANXIETY AGENTS; ANXIETY; AVOIDANCE LEARNING; BICUCULLINE; CYPROHEPTADINE; DISEASE MODELS, ANIMAL; GROWTH HORMONE; GROWTH HORMONE-RELEASING HORMONE; MALE; MAZE LEARNING; METHYSERGIDE; MICE; NEUROTRANSMITTER AGENTS; PHENOXYBENZAMINE; PRAZOSIN; SERMORELIN; SWIMMING;

EID: 84861754176     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2012.04.011     Document Type: Article

References (29)

1. Zarándi M., Horvath J.E., Halmos G., Pinski J., Nagy A., Groot K., et al. Synthesis and biological activities of highly potent antagonists of growth hormone-releasing hormone. Proceedings of the National Academy of Sciences of the United States of America 1994, 91(25):12298-12302.
2. Gola M., Doga M., Bonadonna S., Mazziotti G., Vescovi P.P., Giustina A. Neuroendocrine tumors secreting growth hormone-releasing hormone: pathophysiological and clinical aspects. Pituitary 2006, 9(3):221-229.
3. Schally A.V., Varga J.L., Engel J.B. Antagonists of growth-hormone-releasing hormone: an emerging new therapy for cancer. Nature Clinical Endocrinology and Metabolism 2008, 4:33-43.
4. Telegdy G., Tanaka M., Schally A.V. Effects of the growth hormone-releasing hormone (GH-RH) antagonist on brain functions in mice. Behavioural Brain Research 2011, 224(1):155-158.
5. Tanaka M., Schally A.V., Telegdy G. Neurotransmission of the antidepressant-like effects of the growth hormone-releasing hormone antagonist MZ-4-71. Behavioural Brain Research 2012, 228:388-391.
6. Telegdy G., Tiricz H., Adamik A. Involvement of neurotransmitters in urocortin-induced passive avoidance learning in mice. Brain Research Bulletin 2005, 67:242-247.
7. Pellow S., Chopin P., File S., Briley M. Validation of open: closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. Journal of Neuroscience Methods 1985, 14:149-167.
8. Müller E.E., Locatelli V., Cocchi D. Neuroendocrine control of growth hormone secretion. Physiological Reviews 1999, 79:511-607.
9. Matsubara S., Sato M., Mizobuchi M., Niimi M., Takahara J. Differential gene expression of growth hormone (GH) releasing hormone (GRH) and GRH receptor in various rat tissues. Endocrinology 1995, 136:4147-4150.
10. Obál F. Effects of peptides (DSIP, DSIP analogues, VIP, GRF and CCK) on sleep in the rat. Clinical Neuropharmacology 1986, 9:459-461.
11. Obál F., Alföldi P., Cady A.B., Johannsen L., Sary G., Kruger M. Growth hormone-releasing factor enhances sleep in rats and rabbits. American Journal of Physiology 1988, 255:R310-R316.
12. Obál F., Alt J., Taishi P., Gardi J., Kruger M. Sleep in mice with nonfunctional growth hormone-releasing hormone receptors. American Journal of Physiology. Regulatory, Integrative and Comparative Physiology 2003, 284:R131-R139.
13. Banks W.A., Morley J.E., Farr S.A., Price T.O., Ercal N., Vidaurre I., et al. Effects of a growth hormone-releasing hormone antagonist on telomerase activity, oxidative stress longevity and aging. Proceedings of the National Academy of Sciences of the United States of America 2010, 07:22272-22277.
14. Havt A., Schally A.V., Halmos G., Varga J.L., Toller G.L., Horvath J.E., et al. The expression of the pituitary GH- RH receptor and its splice variants in normal and neoplastic human tissues. Proceedings of the National Academy of Sciences of the United States of America 2005, 102:17424-17429.
15. Arwert Ll Deijen J.B., Müller M., Dreant M.L. Long-term growth hormone treatment preserves GH-induced memory and mood improvement: 10-year follow-up study in GH-deficient adult men. Hormones and Behavior 2005, 47:343-349.
16. Deijen J.B., Arwert Ll Impaired qualitiy of life in hypopituitary adults with growth hormone deficiency: can somatotropin replacement therapy help. Treatments in Endocrinology 2006, 5:243-250.
17. Cogan E. Hormone therapy of ageing: myth and realities. Revue Medicale de Bruxelles 2004, 25:A371-A375.
18. Engin E., Steillbrink J., Treit D., Dickson C.T. Anxiolytic and antidepressant effects of intracerebroventricularly administered somatostatin: behaviour and neurophysiological evidence. Neuroscience 2008, 157:666-676.
19. Engin E., Treit D. Anxiolytic and antidepressant action of somatostatin: the role of sst2 and sst3 receptors. Psychopharmacology 2009, 206:281-289.
20. Vécsei L., Bollók I., Penke B., Telegdy G. Somatostatin and (D-Trp8, D-Cys 24 somatostatin delays extinction and reverse electroconvulsive shock-induced amnesia in rats. Psyhoneuroendocrinology 1986, 11:111-115.
21. Vécsei L., Bollók I., Telegdy G. Comparative studies with cyclic and linear somatostatin on active avoidance behavior and open-field activity of rats. Acta Physiologica Hungarica 1983, 61:43-49.
22. Telegdy G. Neuropeptides and brain function. Frontiers of hormone research 15 1987, Karger, Basel. T. van Wimersma Greidanus (Ed.).
23. Jaeger L.B., Banks W.A., Varga J., Schally A.V. Antagonists of growth hormone-releasing hormone cross the blood-brain barrier: a potential applicability to treatment of brain tumor. Proceedings of the National Academy of Sciences of the United States of America 2005, 102:12495-12500.
24. Enna S.J. Role of gamma-aminobutiric acid in anxiety. Psychopathology 1984, 17(Suppl. 1):15-24.
25. Nestoros J.N. Gabaergic mechanisms and axiety: an overview and a new neurophysiological model. Canadian Journal of Psychiatry 1984, 29:520-529.
26. Versiani M., Cassano G., Perugi G., Benedetti A., Mastalli L., Nardi A.S., et al. Reboxetine, a selective norepinephrine reuptake inhibitors, is an effective and well-tolerated treatment for panic disorder. Journal of Clinical Psychiatry 2002, 63:31-37.
27. Reinhold J.A., Mandos L.A., Rickels K., Lohoff F.W. Pharmacological treatment of generalized anxiety disorder. Expert Opinion on Pharmacotherapy 2011, 12:2457-2467.
28. Katzman M.A. Current considerations in the treatment of generalized anxiety disorder CNS. Drugs 2009, 23:103-120.
29. Hines R.M., Dagvies P.A., Moss S.J., Maguire J. Functional regulation of GABA-A receptors in nervous system. Current Opinion in Neurobiology 2011, 22:1-7.